Dougherty & Company has published a research report on Hologic HOLX and has upgraded the company from Neutral to Buy based on pending data from the Oslo study that recently introduced C-View software.
In the report, Dougherty writes, "We believe the Oslo Study could prove to be as influential (or more) for Tomosynthesis as DMIST was for 2D Mammography. Recall, following publication of the DMIST results in the New England Journal of Medicine in September of 2005, we saw an immediate acceleration in the adoption rate for Hologic's 2D Selenias. We suspect a similar trajectory for Dimensions Tomosynthesis as we get further data points from the Oslo Study."
Dougherty & Company has also raised the price target from $20 to $26 on Hologic, which is currently trading up $0.19 from yesterday's $20.73 closing price.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in